At their respective April board meetings in Chicago, the ACCP Board of Regents and the ACCP Research Institute Board of Trustees approved the release of an RFA (Request for Applications) to study the impact of the implementation of comprehensive medication management (CMM) in primary care medical practices.
ACCP has integrated the practice framework of CMM into its strategic plan, organizational policy and advocacy agenda, professional development initiatives, and research agenda. The practice of CMM is aligned with the core values of the College, has been incorporated into Standards II and III of the Standards of Practice for Clinical Pharmacists, and is gaining increasing support from policy-makers, medical and other professional organizations, primary care providers, and clinical pharmacists.
It is widely recognized that strategies to address the safe, effective, and affordable use of medications in primary care are critical to enhance care transitions, improve health, and control costs. CMM holds promise as an effective, value-added strategy to optimize medication use; however, several questions must be addressed to advance CMM implementation and ensure its widespread uptake and sustainability in primary care medical practices, including:
- Which patients and populations within primary care practices would benefit the most from CMM?
- Among those who receive CMM, what is the impact on quality of care and cost? Are the patients in greatest need of medication optimization receiving CMM, and if so, what are best practices around the duration and frequency of follow-up?
- How can/should CMM be delivered, replicated, scaled, and sustained? In other words, how can medical practices do this most effectively?
- Which medication-related, clinical, and economic performance metrics are most relevant to today’s primary care practices? What are the contributions of the clinical pharmacist to helping the practice achieve these metrics?
- What are the contributions of the clinical pharmacist to the net revenue generated by the practice, and what is the relative return on investment of having the clinical pharmacist embedded in the office or clinic?
Therefore, ACCP has committed up to $2.5 million to fund research that seeks to answer these questions by examining the impact of CMM provided by qualified clinical pharmacists embedded in primary care practices as integral members of the health care team.
Online inquiries and letters of intent will be accepted until June 1, 2015, and notification of the invitation to submit a full proposal will be sent on June 15, 2015. If invited to submit, investigators’ proposals will be due on August 1, 2015, and applicants will be notified of a final decision by September 15, 2015. To obtain more information and to submit an online letter of intent, visit www.accpri.org/CMMRFA.